Press Release

Quest Diagnostics Reports Second Quarter 2019 Financial Results

- Second quarter revenues of $1.95 billion, up 1.8% from 2018
- Second quarter reported diluted earnings per share from continuing operations ("EPS") of $1.51, down 3.9% from 2018; and adjusted diluted EPS of $1.73, down 1.1% from 2018
- Affirms outlook for full-year 2019

SECAUCUS, N.J., July 23, 2019 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the second quarter ended June 30, 2019.

Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

"Our volume growth accelerated in the second quarter due to our expanded network access, and we continued to build momentum through the first half of 2019," said Steve Rusckowski, Chairman, CEO and President. "This strong volume growth combined with our strategy to drive operational excellence helped offset the significant reimbursement pressures we are experiencing this year.  We are excited by our new Preferred Lab Network status within UnitedHealthcare, which represents a multi-year opportunity that will build over time."


Three Months Ended

June 30,


Six Months Ended

June 30,


2019


2018


Change


2019


2018


Change


(dollars in millions, except per share data)

Reported:












Net revenues

$

1,953



$

1,919



1.8

%


$

3,844



$

3,803



1.1

%

Diagnostic Information Services revenues

$

1,872



$

1,835



2.0

%


$

3,684



$

3,638



1.3

%

Revenue per requisition





(2.3)

%






(2.6)

%

Requisition volume





4.4

%






4.0

%

 Organic requisition volume





2.9

%






2.6

%

Operating income (a)

$

307



$

305



0.4

%


$

555



$

577



(3.9)

%

Operating income as a percentage of net revenues (a)

15.7

%


15.9

%


(20) bps


14.4

%


15.2

%


(80) bps

Income from continuing operations attributable to Quest Diagnostics (a)

$

206



$

219



(5.8)

%


$

370



$

396



(6.5)

%

Diluted EPS from continuing operations (a)

$

1.51



$

1.57



(3.9)

%


$

2.71



$

2.84



(4.6)

%

Cash provided by operations

$

321



$

323



(0.9)

%


$

596



$

503



18.5

%

Capital expenditures

$

85



$

78



9.2

%


$

132



$

151



(12.3)

%













Adjusted (b):












Operating income

$

352



$

362



(2.9)

%


$

638



$

687



(7.0)

%

Operating income as a percentage of net revenues

18.0

%


18.9

%


(90) bps


16.6

%


18.1

%


(150) bps

Income from continuing operations attributable to Quest Diagnostics

$

237



$

245



(3.2)

%


$

427



$

456



(6.3)

%

Diluted EPS from continuing operations

$

1.73



$

1.75



(1.1)

%


$

3.13



$

3.27



(4.3)

%

 

(a) 

For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, income from continuing operations attributable to Quest Diagnostics, and diluted EPS from continuing operations, see note 2 of the financial tables attached below.



(b)

Beginning in 2019, the company has changed how it presents adjusted income measures to additionally exclude amortization expense for all periods presented.  We believe this presentation provides investors with additional insight to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business.

 

Outlook for full-year 2019

The company affirmed its outlook for full-year 2019 as follows:


Current Outlook


Low


High

Net revenues

$7.60 billion


$7.75 billion

Net revenue increase

1%


3%

Reported diluted EPS from continuing operations (a)

Greater than $5.29

Adjusted diluted EPS

Greater than $6.40

Cash provided by operations

Approximately $1.3 billion

Capital expenditures

$350 million


$400 million

 

(a)

The outlook for reported diluted EPS from continuing operations was updated to greater than $5.29 from the previous outlook of greater than $5.16 due to the impact of special items in the second quarter.  For a reconciliation of adjusted diluted EPS to reported diluted EPS from continuing operations, see note 5 to the financial tables attached below.

Note on Non-GAAP Financial Measures

As used in this press release the term "reported" refers to measures under the accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefit ("ETB") associated with stock-based compensation and other items.

Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.

Conference Call Information

Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today.  The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: Investor; or via live webcast on the company's website at www.QuestDiagnostics.com/investor.  The company suggests participants dial in approximately 10 minutes before the call.

A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 800-871-1320 for domestic callers or 402-280-1688 for international callers. No passcode is required.  Telephone replays will be available from approximately 10:30 a.m. Eastern Time on July 23, 2019 until midnight Eastern Time on August 6, 2019.  Anyone listening to the call is encouraged to read the company's periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.  Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 46,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

The statements in this press release which are not historical facts may be forward-looking statements.  Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.

This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.

ADDITIONAL TABLES FOLLOW

 

Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Operations
For the Three and Six Months Ended June 30, 2019 and 2018
(in millions, except per share data)
(unaudited)



Three Months Ended

June 30,


Six Months Ended

June 30,


2019


2018


2019


2018

Net revenues

$

1,953



$

1,919



$

3,844



$

3,803










Operating costs and expenses and other operating income:








Cost of services

1,265



1,243



2,509



2,469


Selling, general and administrative

362



351



746



714


Amortization of intangible assets

25



22



49



44


Other operating income, net

(6)



(2)



(15)



(1)


Total operating costs and expenses, net

1,646



1,614



3,289



3,226










Operating income

307



305



555



577










Other income (expense):








Interest expense, net

(45)



(42)



(89)



(83)


Other income (expense), net

3



1



12



(1)


Total non-operating expenses, net

(42)



(41)



(77)



(84)










Income from continuing operations before income taxes and equity in earnings of equity method investees

265



264



478



493


Income tax expense

(63)



(42)



(113)



(94)


Equity in earnings of equity method investees, net of taxes

17



11



30



23


Income from continuing operations

219



233



395



422


Income from discontinued operations, net of taxes

20





20




Net income

239



233



415



422


Less: Net income attributable to noncontrolling interests

13



14



25



26


Net income attributable to Quest Diagnostics

$

226



$

219



$

390



$

396










Amounts attributable to Quest Diagnostics' common stockholders:








Income from continuing operations

$

206



$

219



$

370



$

396


Income from discontinued operations, net of taxes

20





20




Net income

$

226



$

219



$

390



$

396


















Earnings per share attributable to Quest Diagnostics' common stockholders - basic:








Income from continuing operations

$

1.52



$

1.60



$

2.74



$

2.90


Income from discontinued operations

0.15





0.15




Net income

$

1.67



$

1.60



$

2.89



$

2.90


















Earnings per share attributable to Quest Diagnostics' common stockholders - diluted:








Income from continuing operations

$

1.51



$

1.57



$

2.71



$

2.84


Income from discontinued operations

0.15





0.15




Net income

$

1.66



$

1.57



$

2.86



$

2.84


















Weighted average common shares outstanding:








Basic

135



136



134



136


Diluted

136



139



136



139


 

 

Quest Diagnostics Incorporated and Subsidiaries
Consolidated Balance Sheets
June 30, 2019 and December 31, 2018
(in millions, except per share data)
(unaudited)



June 30,
 2019


December 31,
 2018

Assets




Current assets:




Cash and cash equivalents

$

273



$

135


Accounts receivable, net

1,088



1,012


Inventories

105



99


Prepaid expenses and other current assets

100



144


Total current assets

1,566



1,390


Property, plant and equipment, net

1,307



1,288


Operating lease right-of-use assets

511




Goodwill

6,605



6,563


Intangible assets, net

1,172



1,207


Investment in equity method investees

458



436


Other assets

141



119


Total assets

$

11,760



$

11,003






Liabilities and Stockholders' Equity




Current liabilities:




Accounts payable and accrued expenses

$

951



$

1,021


Current portion of long-term debt

807



464


Current portion of long-term operating lease liabilities

146




Total current liabilities

1,904



1,485


Long-term debt

3,169



3,429


Long-term operating lease liabilities

413




Other liabilities

689



745


Redeemable noncontrolling interest

76



77


Stockholders' equity:




Quest Diagnostics stockholders' equity:




Common stock, par value $0.01 per share; 600 shares authorized as of both June 30, 2019 and December 31, 2018; 217 shares issued as of both June 30, 2019 and December 31, 2018

2



2


Additional paid-in capital

2,686



2,667


Retained earnings

7,849



7,602


Accumulated other comprehensive loss

(58)



(59)


Treasury stock, at cost; 82 shares as of both June 30, 2019 and December 31, 2018

(5,020)



(4,996)


Total Quest Diagnostics stockholders' equity

5,459



5,216


Noncontrolling interests

50



51


Total stockholders' equity

5,509



5,267


Total liabilities and stockholders' equity

$

11,760



$

11,003


 

 

Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Cash Flows
For the Six Months Ended June 30, 2019 and 2018
(in millions)
(unaudited)



Six Months Ended June 30,


2019


2018

Cash flows from operating activities:




Net income

$

415



$

422


Adjustments to reconcile net income to net cash provided by operating activities:




Depreciation and amortization

165



151


Provision for doubtful accounts

5




Deferred income tax provision

13



39


Stock-based compensation expense

32



34


Other, net

(33)



18


Changes in operating assets and liabilities:




Accounts receivable

(81)



(127)


Accounts payable and accrued expenses

27



(64)


Income taxes payable

15



(7)


Other assets and liabilities, net

38



37


Net cash provided by operating activities

596



503






Cash flows from investing activities:




Business acquisitions, net of cash acquired

(56)



(165)


Capital expenditures

(132)



(151)


Increase in investments and other assets

(14)



(14)


Net cash used in investing activities

(202)



(330)






Cash flows from financing activities:




Proceeds from borrowings

1,484



1,520


Repayments of debt

(1,448)



(1,553)


Purchases of treasury stock

(103)



(50)


Exercise of stock options

66



71


Employee payroll tax withholdings on stock issued under stock-based compensation plans

(16)



(20)


Dividends paid

(143)



(129)


Distributions to noncontrolling interest partners

(27)



(28)


Contributions from noncontrolling interest partners



4


Other financing activities, net

(69)



7


Net cash used in financing activities

(256)



(178)






Net change in cash and cash equivalents and restricted cash

138



(5)


Cash and cash equivalents and restricted cash, beginning of period

135



137


Cash and cash equivalents and restricted cash, end of period

$

273



$

132






Cash and cash equivalents

$

273



$

132


Restricted cash




Cash and cash equivalents and restricted cash, end of period

$

273



$

132






Cash paid during the period for:




Interest

$

91



$

86


Income taxes

$

83



$

41



 

 

Notes to Financial Tables


1)  The computation of basic and diluted earnings per common share is as follows:



Three Months Ended

June 30,


Six Months Ended

June 30,


2019


2018


2019


2018


(in millions, except per share data)

Amounts attributable to Quest Diagnostics' common stockholders:








Income from continuing operations

$

206



$

219



$

370



$

396


Income from discontinued operations, net of taxes

20





20




Net income attributable to Quest Diagnostics' common stockholders

$

226



$

219



$

390



$

396










Income from continuing operations

$

206



$

219



$

370



$

396


Less: earnings allocated to participating securities





1



1


Earnings available to Quest Diagnostics' common stockholders - basic and diluted

$

206



$

219



$

369



$

395










Weighted average common shares outstanding - basic

135



136



134



136


Effect of dilutive securities:








Stock options and performance share units

1



3



2



3


Weighted average common shares outstanding - diluted

136



139



136



139










Earnings per share attributable to Quest Diagnostics' common stockholders - basic:








Income from continuing operations

$

1.52



$

1.60



$

2.74



$

2.90


Income from discontinued operations

0.15





0.15




Net income

$

1.67



$

1.60



$

2.89



$

2.90










Earnings per share attributable to Quest Diagnostics' common stockholders - diluted:








Income from continuing operations

$

1.51



$

1.57



$

2.71



$

2.84


Income from discontinued operations

0.15





0.15




Net income

$

1.66



$

1.57



$

2.86



$

2.84


 

 

2)  The following tables reconcile reported GAAP results to non-GAAP adjusted results:



Three Months Ended June 30, 2019

(dollars in millions, except per share data)


Operating income


Operating income as a percentage of net revenues


Income tax expense (c)


Equity in earnings of equity method investees, net of taxes


Income from continuing operations  attributable to Quest Diagnostics


Diluted EPS from continuing operations

As reported

$

307



15.7

%


$

(63)



$

17



$

206



$

1.51


Restructuring and integration charges (a)

26



1.3



(7)





19



0.14


Other (b)

(6)



(0.3)







(6)



(0.04)


Amortization expense

25



1.3



(7)



5



23



0.16


ETB





(5)





(5)



(0.04)


As adjusted

$

352



18.0

%


$

(82)



$

22



$

237



$

1.73









Six Months Ended June 30, 2019

(dollars in millions, except per share data)


Operating income


Operating income as a percentage of net revenues


Income tax expense (c)


Equity in earnings of equity method investees, net of taxes


Income from continuing operations attributable to Quest Diagnostics


Diluted EPS from continuing operations

As reported

$

555



14.4

%


$

(113)



$

30



$

370



$

2.71


Restructuring and integration charges (a)

48



1.3



(13)





35



0.26


Other (b)

(14)



(0.4)



(1)





(15)



(0.10)


Amortization expense

49



1.3



(14)



10



45



0.32


ETB





(8)





(8)



(0.06)


As adjusted

$

638



16.6

%


$

(149)



$

40



$

427



$

3.13









Three Months Ended June 30, 2018

(dollars in millions, except per share data)


Operating income


Operating income as a percentage of net revenues


Income tax expense (c)


Equity in earnings of equity method investees, net of taxes


Income from continuing operations attributable to Quest Diagnostics


Diluted EPS from continuing operations

As reported

$

305



15.9

%


$

(42)



$

11



$

219



$

1.57


Restructuring and integration charges (a)

25



1.3



(6)





19



0.13


Other (b)

10



0.5



(3)





7



0.05


Amortization expense

22



1.2



(6)



4



20



0.14


ETB





(5)





(5)



(0.04)


Certain income tax benefits (d)





(15)





(15)



(0.10)


As adjusted

$

362



18.9

%


$

(77)



$

15



$

245



$

1.75









Six Months Ended June 30, 2018

(dollars in millions, except per share data)


Operating income


Operating income as a percentage of net revenues


Income tax expense (c)


Equity in earnings of equity method investees, net of taxes


Income from continuing operations attributable to Quest Diagnostics


Diluted EPS from continuing operations

As reported

$

577



15.2

%


$

(94)



$

23



$

396



$

2.84


Restructuring and integration charges (a)

56



1.5



(14)





42



0.30


Other (b)

10



0.2



(3)





7



0.05


Amortization expense

44



1.2



(13)



8



39



0.28


ETB





(13)





(13)



(0.10)


Certain income tax benefits (d)





(15)





(15)



(0.10)


As adjusted

$

687



18.1

%


$

(152)



$

31



$

456



$

3.27


 

(a) 

For the three and six months ended June 30, 2019, represents costs primarily associated with systems conversions and integration incurred in connection with further restructuring and integrating our business.  For the three and six months ended June 30, 2018, represents costs primarily associated with workforce reductions, systems conversions and integration incurred in connection with further restructuring and integrating our business. The following table summarizes the pre-tax impact of restructuring and integration charges on the company's consolidated statements of operations:

 


Three Months Ended

June 30,


Six Months Ended

June 30,


2019


2018


2019


2018


(dollars in millions)

Cost of services

$

11



$

14



$

22



$

26


Selling, general and administrative

15



11



26



29


Other operating income, net







1


Operating income

$

26



$

25



$

48



$

56


 

(b) 

For the three months ended June 30, 2019, the pre-tax impact primarily represents a gain associated with the decrease in the fair value of the contingent consideration accrual associated with our ReproSource, Inc. acquisition.  For the six months ended June 30, 2019, the pre-tax impact primarily represents a gain associated with an insurance claim for hurricane related losses, and a gain associated with the decrease in the fair value of the contingent consideration accrual associated with our ReproSource, Inc. acquisition partially offset by non-cash asset impairment charges. For the three and six months ended June 30, 2018, the pre-tax impact primarily represents costs incurred related to certain legal matters partially offset by a gain associated with an insurance claim for hurricane related losses.  The following table summarizes the pre-tax impact of these other items on the company's consolidated statements of operations:

 


Three Months Ended

June 30,


Six Months Ended

June 30,


2019


2018


2019


2018


(dollars in millions)

Cost of sales

$



$

11



$



$

11


Selling, general and administrative





1




Other operating income, net

(6)



(1)



(15)



(1)


Operating income

$

(6)



$

10



$

(14)



$

10


 

(c)

For restructuring and integration charges, other items and amortization expense, income tax impacts, where recorded, were primarily calculated using combined tax rates of 25.5% for both 2019 and 2018.  For the gain associated with an insurance claim for hurricane related losses in 2019, there was no net income tax expense as the company is able to utilize net operating loss carryforwards for which a valuation allowance had previously been established.  For the gain in 2019 associated with the decrease in the fair value of the contingent consideration accrual associated with our ReproSource, Inc. acquisition, there was no net income tax expense as the gain is non-taxable. 



(d)

Represents an income tax benefit associated with a change in a tax return accounting method that enabled the company to accelerate the deduction of certain expenses on its 2017 tax return at the federal corporate statutory tax rate in effect during 2017.



3)

Discontinued operations, net of taxes, for the three and six months ended June 30, 2019 includes discrete tax benefits of $20 million associated with the favorable resolution of certain tax contingencies related to Nichols Institute Diagnostics, a test kit manufacturing subsidiary whose operations were discontinued in 2006.



4)

For the three months ended June 30, 2019, the company repurchased 0.5 million shares of its common stock for $50 million.  For the six months ended June 30, 2019, the company repurchased 1.1 million shares of its common stock for $100 million.  As of June 30, 2019, $0.5 billion remained available under the company's share repurchase authorizations.       


5)

The outlook for adjusted diluted EPS represents management's estimates for the full-year 2019 before the impact of special items, including ETB and amortization expense.  Further impacts to earnings related to special items may occur throughout 2019.  Additionally, the amount of ETB is dependent upon employee stock option exercises and the company's stock price, which are difficult to predict.  The following table reconciles our 2019 outlook for adjusted diluted EPS to the corresponding amounts determined under GAAP:

 

Diluted earnings per common share from continuing operations

$

5.29


Restructuring and integration charges (a)

0.65


Other

(0.10)


Amortization expense (b)

0.62


ETB

(0.06)


Adjusted diluted EPS

$

6.40


 

(a) 

Represents estimated full-year pre-tax charges of $118 million primarily associated with systems conversions and integration costs incurred in connection with further restructuring and integrating our business.  Income tax benefits were calculated using a combined tax rate of 25.5%.



(b) 

Represents the estimated impact of amortization expense for 2019 on the calculation of adjusted diluted EPS.  Amortization expense used in the calculation is as follows (dollars in millions):

 

Amortization of intangible assets

$

98


Amortization expense included in equity in earnings of equity method investees, net of taxes

15


Total pre-tax amortization expense

$

113




Total amortization expense, net of an estimated tax benefit using a combined tax rate of 25.5%

$

84


 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/quest-diagnostics-reports-second-quarter-2019-financial-results-300888934.html

SOURCE Quest Diagnostics Incorporated

Denny Moynihan, Quest Diagnostics (Media): 973-520-2800, Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900